IPCALAB Intraday Analysis...

IPCALAB Share Price

Open 545.00 Change Price %
High 554.00 1 Day 3.70 0.68
Low 543.00 1 Week -6.85 -1.23
Close 549.80 1 Month 2.15 0.39
Volume 27209 1 Year -69.25 -11.19
52 Week High 679.00
52 Week Low 404.00
IPCALAB Important Levels
Resistance 2 560.00
Resistance 1 555.80
Pivot 548.93
Support 1 543.81
Support 2 539.60
NSE INDIA Most Active Stocks
JPASSOCIAT 10.20 5.15%
SUZLON 15.70 0.64%
JINDALSTEL 80.20 3.48%
ADANIPOWER 37.85 2.30%
HINDALCO 177.00 3.48%
VEDL 244.40 3.52%
GMRINFRA 12.55 0.00%
BHEL 132.40 3.48%
POWERGRID 198.45 0.35%
NHPC 29.80 -0.50%
More..
NSE INDIA Top Gainers Stocks
RASOYPR 0.20 33.33%
FMNL 45.00 20.00%
INDOTHAI 25.05 19.86%
HOTELRUGBY 4.60 19.48%
OILCOUNTUB 52.05 17.89%
PANACEABIO 148.30 16.59%
ELGIRUBCO 55.95 15.96%
TRIL 437.90 15.42%
WEIZFOREX 244.90 14.81%
JINDCOT 16.85 14.63%
More..
NSE INDIA Top Losers Stocks
VKSPL 0.10 -33.33%
FCSSOFT 0.30 -14.29%
SPYL 1.00 -13.04%
NAKODA 0.40 -11.11%
UNITEDTEA 303.95 -8.55%
AGARIND 332.80 -7.14%
ASIL 0.70 -6.67%
CELESTIAL 21.30 -6.17%
KRIDHANINF 57.75 -6.02%
SUNDARAM 4.05 -5.81%
More..

IPCA Laboratories Limited (NSE: IPCALAB)

IPCALAB Technical Analysis 1.5
As on 18th Jan 2017 IPCALAB Share Price closed @ 549.80 and we RECOMMEND Buy for LONG-TERM with Stoploss of 535.23 & Sell for SHORT-TERM with Stoploss of 550.11 we also expect STOCK to react on Following IMPORTANT LEVELS.
IPCALAB Target for January
1st Target up-side 574.72
2nd Target up-side 603.92
3rd Target up-side 633.12
1st Target down-side 491.38
2nd Target down-side 462.18
3rd Target down-side 432.98
IPCALAB Synopsis Technicals View
50 Day EMA N/A (Short Term)
N/A
100 Day EMA N/A (Mid Term) N/A
200 Day EMA N/A (Long Term) N/A
MACD (12 26 9) N/A N/A
RSI (14) N/A N/A
MFI (14) N/A N/A
CCI (20) N/A N/A
WILLIAM %R (14) N/A N/A
ADX (14) N/A N/A
PSAR N/A N/A
10 Day Avg Volume N/A
IPCALAB Other Details
Segment EQ
Market Capital 34699423744.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.ipcalabs.com
IPCALAB Address
IPCALAB
142 AB, Kandivli Industrial Estate
Kandivli (West)
Mumbai, 400067
India
Phone: 91 22 6647 4747
Fax: 91 22 2868 6954
Interactive Technical Analysis Chart IPCA Laboratories Limited ( IPCALAB NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on IPCA Laboratories Limited
IPCALAB Business Profile
Ipca Labs is in the Pharmaceuticals - Bulk Drugs and Formulation sector. Ipca Laboratories (IPCA), a recognized trading house, exports to over 108 countries. Over 60% of its turnover comes from specialty formulations such as anti-malarials, anti-emetics, anti-hypertensives, antibiotics and other drugs. The balance comes from bulk drugs, drug intermediates, generic formulations, hospital products, ..etc. The company works out of its various divisions namely general pharma division, Intima division, Activa division, 3C division, Innova division and Hycare division. It is the largest Indian manufacturer of anti-malarial bulk drug chloroquine phosphate. The formulations manufacturing unit of the company in Athal, Silvassa is being expanded and upgraded to meet the growing formulations export business. The company exports formulations as well as APIs to several Asian countries. The company markets branded formulations to Sri Lanka, Myanmar and Vietnam. During 2004-2005, the company introduced 15 new products in the domestic market. New products introduced during the last three financial years now constitute nearly 24% of its domestic formulations sales. The company is setting up new formulations manufacturing unit at the special economic zone (SEZ) Indore. IPCA currently has five wholly-owned overseas subsidiary companies after amalgamation of the wholly-owned subsidiary Innotech Pharma with the company. The company plans to develop various APIs/intermediates having good potential for exports and local market. It plans additional investment in manpower, latest instrumentation to upgrade and strengthen R&D facilities. Also, the company aims at developing newer drug delivery systems along with developing formulations for developed market and bio-equivalence studies of the same. The current market capitalisation stands at Rs 8,614.35 crore.The company has reported a consolidated sales of Rs 1292.64 crore and a Net Profit of Rs 95.07 crore for the quarter ended Mar 2009. The company management includes Premchand Godha - Chairman & Managing Director, Ajit Kumar Jain - Joint Managing Director, Pranay Godha - Executive Director, Prashant Godha - Executive Director, Madhukar R Chandurkar - Director, Babulal Jain - Director, V V Subba Rao - Director, Anand T Kusre - Director, Dev Parkash Yadava - Director, Ramakanta Panda - Director. It is listed on the BSE with a BSE Code of 524494 and the NSE with an NSE Code of IPCALAB. Its Registered office is at 48, Kandivli Industrial Estate, Kandivli (West), Mumbai,Maharashtra - 400067.